PROTACs: A Promising Therapeutic Approach for Hematologic Malignancies

Hematologic malignancies continue to pose an imminent threat to healthcare professionals around the globe, resulting in the development of novel therapeutic strategies. Proteolysis-targeting chimeras (PROTACs) have developed as a promising approach for targeted protein degradation. The use of PROTACs overcomes the limitations associated with traditional inhibitors. PROTACs use the ubiquitin-proteasome system to target and selectively degrade oncogenic proteins. PROTACs offer enhanced specificity, reduced resistance, and improved efficacy in treating hematologic cancers, including leukemia, lymphoma, and myeloma. This report reviews the mechanism of action of PROTACs, focusing on their ability to target undruggable proteins and modulate key signaling pathways implicated in hematologic malignancies. This paper also discusses the recent advancements in PROTAC-based therapeutics. The preclinical and clinical efficacy of clinical candidates such as NX-2127, SIAIS178, and ARV-771 are discussed. The importance of emerging strategies like CRBN and Von Hippel-Lindau-based degraders, ligand modifications, and combinatorial therapies are assessed in this paper. Different challenges associated with PROTAC development, such as drug stability, cellular permeability, and potential off-target effects, are also reported in the paper. The clinical success of PROTACs has the potential to revolutionize targeted cancer therapy by providing a novel, potent, and reversible approach to protein degradation. Although challenges remain, ongoing research and optimization will help develop the next generation of PROTAC-based therapeutics, improving outcomes for patients with hematologic malignancies. This review provides a detailed overview of the therapeutic potential of PROTACs, highlighting their clinical significance and prospects in precision oncology.